Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis
Harpreet Singh,1 Liam Wilson,2 Tom Tencer,3 Jinender Kumar3 1Health Economics & Market Access (HEMA), Amaris Consulting Ltd, Toronto, ON, Canada; 2Health Economics & Market Access (HEMA), Amaris Consulting Ltd, Shanghai, People’s Republic of China; 3Bristol Myers Squibb, Princeton, NJ, USACo...
Main Authors: | Singh H, Wilson L, Tencer T, Kumar J |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-02-01
|
Series: | ClinicoEconomics and Outcomes Research |
Subjects: | |
Online Access: | https://www.dovepress.com/systematic-literature-review-of-real-world-evidence-on-dose-escalation-peer-reviewed-fulltext-article-CEOR |
Similar Items
-
Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries
by: Alessandro Armuzzi, et al.
Published: (2023-01-01) -
Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis
by: Genta Uchida, et al.
Published: (2023-06-01) -
Tofacitinib in Treatment-Refractory Moderate to Severe Ulcerative Colitis: Real-World Experience from a Retrospective Multicenter Observational Study
by: Peter Hoffmann, et al.
Published: (2020-07-01) -
Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore
by: Scott D. Lee, et al.
Published: (2023-02-01) -
Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment
by: Hiroshi Nakase
Published: (2023-07-01)